Lifileucel, sold under the brand name Amtagvi, is an adoptive T cell therapy used for the treatment of melanoma. Specifically, lifileucel is a tumor-derived T cell immunotherapy composed of a recipient's own T cells. From Wikipedia
Presented at ASCO, trial data highlight sustained tumour reduction with lifileucel, paving the way for pembrolizumab combination studies.
